01786nas a2200361   4500000000100000008004100001260001300042653001000055653001400065653001000079653002200089653001100111653001200122653001800134653002400152653001500176653002000191653001600211100001500227700001300242700001300255700001300268700001500281700001100296700001400307700001500321700001500336245009100351300001200442490000700454520094900461022001401410       1998                            d  c1998 Jul10aAdult10aArgentina10aChild10aFollow-Up Studies10aHumans10aleprosy10aMycobacterium10aMycobacterium bovis10aPrevalence10aTuberculin Test10aVaccination1 aBottasso O1 aMerlin V1 aCannon L1 aCannon H1 aIngledew N1 aKeni M1 aHartopp R1 aStanford C1 aStanford J00aStudies of vaccination of persons in close contact with leprosy patients in Argentina.  a1166-710 v163 a<p>A total of 670 adults living or working with leprosy patients, were examined for a BCG vaccination scar, and skin-tested with four new tuberculins. Based on the results 513 were vaccinated, 65 with Bacille de Calmette et Guérin (BCG) alone, 66 with BCG plus killed Mycobacterium vaccae and 382 with killed M. vaccae alone. Skin-testing was repeated 2-3 years later on 344 subjects, when all three vaccines were found to have been highly successful in increasing responses to Tuberculin and Leprosin A (p < 0.0005) with increased immune recognition of common and species-specific antigens. Mean diameters of induration to each skin-test were greatest in recipients of BCG alone (p < 0.05), which suggests that better immuno-regulation occurs after receiving vaccines that incorporate M. vaccae. The results suggest 10(8) M. vaccae alone might prove a valuable future vaccine, which would not require selective pre-vaccination procedures.</p>  a0264-410X